Guardian Pharmacy Services (NYSE:GRDN) Reaches New 1-Year High – What’s Next?

Guardian Pharmacy Services, Inc. (NYSE:GRDN)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $41.79 and last traded at $41.58, with a volume of 124747 shares changing hands. The stock had previously closed at $40.80.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GRDN shares. Raymond James Financial restated an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Wall Street Zen cut Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group restated a “buy” rating on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Truist Financial lifted their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Guardian Pharmacy Services Trading Down 0.0%

The firm has a market cap of $2.03 billion, a PE ratio of 49.14, a price-to-earnings-growth ratio of 2.57 and a beta of 0.08. The stock has a fifty day simple moving average of $37.57 and a two-hundred day simple moving average of $33.54.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The company had revenue of $336.60 million during the quarter, compared to analyst estimates of $329.89 million. During the same quarter in the previous year, the firm earned $0.22 earnings per share. Guardian Pharmacy Services’s revenue was up 2.2% on a year-over-year basis. As a group, sell-side analysts predict that Guardian Pharmacy Services, Inc. will post 1.18 earnings per share for the current fiscal year.

Insider Activity at Guardian Pharmacy Services

In other news, Director Thomas J. Salentine, Jr. sold 3,570,677 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $105,977,693.36. Following the completion of the transaction, the director owned 4,469,316 shares of the company’s stock, valued at approximately $132,649,298.88. The trade was a 44.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kendall Forbes sold 346,672 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $10,289,224.96. Following the transaction, the insider directly owned 453,256 shares of the company’s stock, valued at $13,452,638.08. The trade was a 43.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,726,405 shares of company stock valued at $288,679,700 in the last ninety days. Insiders own 32.96% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GRDN. Valiant Capital Management L.P. lifted its position in Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock worth $37,085,000 after buying an additional 167,741 shares during the last quarter. Wellington Management Group LLP lifted its position in Guardian Pharmacy Services by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock worth $30,000,000 after buying an additional 36,072 shares during the last quarter. Franklin Resources Inc. lifted its position in Guardian Pharmacy Services by 8.2% in the 3rd quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock worth $27,705,000 after buying an additional 80,033 shares during the last quarter. Vanguard Group Inc. lifted its position in Guardian Pharmacy Services by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock worth $27,675,000 after buying an additional 88,296 shares during the last quarter. Finally, Boston Partners lifted its position in Guardian Pharmacy Services by 0.7% in the 4th quarter. Boston Partners now owns 1,054,636 shares of the company’s stock worth $31,995,000 after buying an additional 7,759 shares during the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.